Logo image of LGND

LIGAND PHARMACEUTICALS (LGND) Stock Fundamental Analysis

USA - NASDAQ:LGND - US53220K5048 - Common Stock

204.875 USD
+4.01 (+2%)
Last: 11/17/2025, 11:09:12 AM
Fundamental Rating

5

LGND gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While LGND has a great health rating, its profitability is only average at the moment. LGND is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year LGND was profitable.
LGND had a positive operating cash flow in the past year.
In multiple years LGND reported negative net income over the last 5 years.
Each year in the past 5 years LGND had a positive operating cash flow.
LGND Yearly Net Income VS EBIT VS OCF VS FCFLGND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

LGND's Return On Assets of -8.00% is fine compared to the rest of the industry. LGND outperforms 69.27% of its industry peers.
The Return On Equity of LGND (-9.16%) is better than 74.48% of its industry peers.
Industry RankSector Rank
ROA -8%
ROE -9.16%
ROIC N/A
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
LGND Yearly ROA, ROE, ROICLGND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

1.3 Margins

In the last couple of years the Operating Margin of LGND has declined.
LGND has a Gross Margin of 93.05%. This is amongst the best in the industry. LGND outperforms 94.27% of its industry peers.
In the last couple of years the Gross Margin of LGND has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for LGND so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.05%
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
LGND Yearly Profit, Operating, Gross MarginsLGND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300 400 500

More info and screens

7

2. Health

2.1 Basic Checks

LGND does not have a ROIC to compare to the WACC, probably because it is not profitable.
LGND has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LGND has been increased compared to 5 years ago.
LGND has a worse debt/assets ratio than last year.
LGND Yearly Shares OutstandingLGND Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
LGND Yearly Total Debt VS Total AssetsLGND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

LGND has an Altman-Z score of 20.87. This indicates that LGND is financially healthy and has little risk of bankruptcy at the moment.
LGND has a Altman-Z score of 20.87. This is amongst the best in the industry. LGND outperforms 92.19% of its industry peers.
There is no outstanding debt for LGND. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 20.87
ROIC/WACCN/A
WACC8.85%
LGND Yearly LT Debt VS Equity VS FCFLGND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

LGND has a Current Ratio of 5.45. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.45, LGND is in the better half of the industry, outperforming 70.31% of the companies in the same industry.
A Quick Ratio of 5.21 indicates that LGND has no problem at all paying its short term obligations.
LGND's Quick ratio of 5.21 is fine compared to the rest of the industry. LGND outperforms 70.31% of its industry peers.
Industry RankSector Rank
Current Ratio 5.45
Quick Ratio 5.21
LGND Yearly Current Assets VS Current LiabilitesLGND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.26% over the past year.
LGND shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.44% yearly.
LGND shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.28%.
The Revenue has been growing slightly by 6.80% on average over the past years.
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
Revenue 1Y (TTM)27.28%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%

3.2 Future

Based on estimates for the next years, LGND will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.78% on average per year.
LGND is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.82% yearly.
EPS Next Y22.63%
EPS Next 2Y16.57%
EPS Next 3Y15.36%
EPS Next 5Y16.78%
Revenue Next Year31.46%
Revenue Next 2Y22.03%
Revenue Next 3Y20.53%
Revenue Next 5Y20.82%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LGND Yearly Revenue VS EstimatesLGND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
LGND Yearly EPS VS EstimatesLGND Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 28.10, the valuation of LGND can be described as expensive.
78.13% of the companies in the same industry are more expensive than LGND, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of LGND to the average of the S&P500 Index (25.89), we can say LGND is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 26.41, the valuation of LGND can be described as expensive.
Based on the Price/Forward Earnings ratio, LGND is valued a bit cheaper than 73.96% of the companies in the same industry.
LGND is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.59, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 28.1
Fwd PE 26.41
LGND Price Earnings VS Forward Price EarningsLGND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 76.04% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, LGND is valued a bit cheaper than the industry average as 75.52% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 78.98
EV/EBITDA 173.69
LGND Per share dataLGND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

LGND's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as LGND's earnings are expected to grow with 15.36% in the coming years.
PEG (NY)1.24
PEG (5Y)2.09
EPS Next 2Y16.57%
EPS Next 3Y15.36%

More info and screens

0

5. Dividend

5.1 Amount

LGND does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIGAND PHARMACEUTICALS

NASDAQ:LGND (11/17/2025, 11:09:12 AM)

204.875

+4.01 (+2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners100.32%
Inst Owner Change87.82%
Ins Owners1.69%
Ins Owner Change-0.57%
Market Cap4.02B
Revenue(TTM)167.13M
Net Income(TTM)-75.86M
Analysts84.62
Price Target186.79 (-8.83%)
Short Float %6.17%
Short Ratio6.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.98%
Min EPS beat(2)7.61%
Max EPS beat(2)10.36%
EPS beat(4)4
Avg EPS beat(4)14.14%
Min EPS beat(4)4.63%
Max EPS beat(4)33.98%
EPS beat(8)8
Avg EPS beat(8)38.28%
EPS beat(12)12
Avg EPS beat(12)65.25%
EPS beat(16)15
Avg EPS beat(16)61.42%
Revenue beat(2)2
Avg Revenue beat(2)10.64%
Min Revenue beat(2)6.44%
Max Revenue beat(2)14.84%
Revenue beat(4)4
Avg Revenue beat(4)13.45%
Min Revenue beat(4)6.44%
Max Revenue beat(4)24.96%
Revenue beat(8)8
Avg Revenue beat(8)14.01%
Revenue beat(12)11
Avg Revenue beat(12)13.22%
Revenue beat(16)14
Avg Revenue beat(16)14.34%
PT rev (1m)0%
PT rev (3m)25.43%
EPS NQ rev (1m)0.22%
EPS NQ rev (3m)3.93%
EPS NY rev (1m)0%
EPS NY rev (3m)12.11%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)5.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.66%
Valuation
Industry RankSector Rank
PE 28.1
Fwd PE 26.41
P/S 21.41
P/FCF 78.98
P/OCF 76.36
P/B 4.85
P/tB 14.17
EV/EBITDA 173.69
EPS(TTM)7.29
EY3.56%
EPS(NY)7.76
Fwd EY3.79%
FCF(TTM)2.59
FCFY1.27%
OCF(TTM)2.68
OCFY1.31%
SpS9.57
BVpS42.27
TBVpS14.45
PEG (NY)1.24
PEG (5Y)2.09
Graham Number83.27
Profitability
Industry RankSector Rank
ROA -8%
ROE -9.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.05%
FCFM 27.11%
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 5.04%
Cap/Sales 0.93%
Interest Coverage N/A
Cash Conversion 259.88%
Profit Quality N/A
Current Ratio 5.45
Quick Ratio 5.21
Altman-Z 20.87
F-Score5
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
EPS Next Y22.63%
EPS Next 2Y16.57%
EPS Next 3Y15.36%
EPS Next 5Y16.78%
Revenue 1Y (TTM)27.28%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
Revenue Next Year31.46%
Revenue Next 2Y22.03%
Revenue Next 3Y20.53%
Revenue Next 5Y20.82%
EBIT growth 1Y-288.32%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year478.11%
EBIT Next 3Y137.22%
EBIT Next 5Y79.19%
FCF growth 1Y-48.59%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-51.27%
OCF growth 3Y7.19%
OCF growth 5YN/A

LIGAND PHARMACEUTICALS / LGND FAQ

What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?

ChartMill assigns a fundamental rating of 5 / 10 to LGND.


Can you provide the valuation status for LIGAND PHARMACEUTICALS?

ChartMill assigns a valuation rating of 4 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.


How profitable is LIGAND PHARMACEUTICALS (LGND) stock?

LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 4 / 10.


What is the valuation of LIGAND PHARMACEUTICALS based on its PE and PB ratios?

The Price/Earnings (PE) ratio for LIGAND PHARMACEUTICALS (LGND) is 28.1 and the Price/Book (PB) ratio is 4.85.


Can you provide the expected EPS growth for LGND stock?

The Earnings per Share (EPS) of LIGAND PHARMACEUTICALS (LGND) is expected to grow by 22.63% in the next year.